MPM BioImpact — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.
BiotechMedical DevicesWaltham, US
Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)Oxana Beskrovnaya, Ph.D.(Executive Officer)
BoardLawrence Klein, Ph.D.(Director)
Co-investorsAtlas VentureVida VenturesForbionHercules Capital, Inc.
BiotechOklahoma City, US
Scott Rollins, Ph.D.(Executive Officer, Director)David Facloner(Executive Officer)Richard Alvarez(Executive Officer)Rodger McEver, M.D.(Director)Russell Rother(Executive Officer)
Board seatTodd Foley· per SEC Form D · filed Dec 2020
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)
BoardChristoph Westphal(Director)
Board seatLuke EvninBriggs Morrison· per SEC Form D
Co-investorsDC Investment PartnersK2 HealthVenturesLongwood FundRA CapitalTaiho Ventures, LLC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.